Literature DB >> 10602893

Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.

J Thiele1, H M Kvasnicka, R Fischer.   

Abstract

The aim of this review is to evaluate morphological characteristics of the different subtypes of chronic myeloproliferative disorders (MPDs) derived by applying immunohistochemical and morphometric techniques to bone marrow biopsies and to combine these results with relevant clinical parameters. In comparison to control specimens, a significant decrease in erythroid precursors is determinable in chronic myeloid leukemia (CML), while this cell lineage is most prominent in polycythemia vera (PV) and moderately to markedly reduced in idiopathic myelofibrosis (IMF). On the other hand, neutrophilic granulopoiesis shows a predominance in CML and a relevant increase in PV, but no conspicuous changes are detectable in essential thrombocythemia (ET). CML is characterized by a prevalent growth of dwarflike micromegakaryocytes, occurring in particular in the so-called megakaryocyte-rich subtypes (about 30%). This finding differs significantly from the pleomorphous aspect, i.e. , clusters of small to giant-sized megakaryocytes in PV and the grossly abnormal (dysplastic) appearance of this cell lineage in patients with IMF. Similar cytological abnormalities of megakaryopoiesis consistent with maturation defects are never encountered in ET. The incidence of mature (resident) macrophages (phagocytic reticular cells) is significantly enhanced in IMF in comparison to the other MPDs and controls. Moreover, there is a striking difference in the density of reticulin-collagen fibers, ranging from normal (ET) to extreme values (IMF). In IMF more than 80% of the patients present with some degree of myelofibrosis-osteosclerosis at diagnosis, while the rest show an initial prefibrotic, hypercellular stage. This feature deserves special attention since, when accompanied by thrombocythemia, it may simulate ET. Sequential bone marrow biopsies in patients with IMF disclose that evolution of myelofibrosis is progressive, but occurs at a variable and unpredictable speed. A synoptical approach regarding clinical diagnosis and histological subtyping of MPDs is explicitly recommended and demonstrated by sets of diagnostic criteria. This rationale requires equal consideration of laboratory data and morphology by clinicians to include well-defined subtypes of MPDs into prospective management studies. Furthermore, it may even warrant follow-up studies and repeated bone marrow examinations in initially unclassifiable cases.

Entities:  

Mesh:

Year:  1999        PMID: 10602893     DOI: 10.1007/s002770050546

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

1.  Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.

Authors:  Zbigniew Rudzki; Rafał Kawa; Krzysztof Okoñ; Ewa Szczygieł; Jerzy Stachura
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

Review 2.  Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 3.  Hematopoietic cell regulation of osteoblast proliferation and differentiation.

Authors:  Monique Bethel; Edward F Srour; Melissa A Kacena
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

4.  A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.

Authors:  Ceyla Konca Degertekin; Zübeyde Nur Ozkurt; Nalan Akyürek; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-07       Impact factor: 0.900

5.  A novel role for thrombopoietin in regulating osteoclast development in humans and mice.

Authors:  Monique Bethel; Calvin L T Barnes; Amanda F Taylor; Ying-Hua Cheng; Brahmananda R Chitteti; Mark C Horowitz; Angela Bruzzaniti; Edward F Srour; Melissa A Kacena
Journal:  J Cell Physiol       Date:  2015-09       Impact factor: 6.384

6.  Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation.

Authors:  Wendy A Ciovacco; Ying-Hua Cheng; Mark C Horowitz; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

7.  [Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

Authors:  J Thiele; H M Kvasnicka; E Varus; S Kriener; K Engels; P Staib; E S Ollig; M Griesshammer; C F Waller; H Pfeifer; A Schmitt-Gräff
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

8.  Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells.

Authors:  Ying-Hua Cheng; Drew A Streicher; David L Waning; Brahmananda R Chitteti; Rita Gerard-O'Riley; Mark C Horowitz; Joseph P Bidwell; Fredrick M Pavalko; Edward F Srour; Lindsey D Mayo; Melissa A Kacena
Journal:  J Cell Physiol       Date:  2015-03       Impact factor: 6.384

9.  Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation.

Authors:  Ying-Hua Cheng; R Adam Hooker; Khanh Nguyen; Rita Gerard-O'Riley; David L Waning; Brahmananda R Chitteti; Tomas E Meijome; Hui Lin Chua; Artur P Plett; Christie M Orschell; Edward F Srour; Lindsey D Mayo; Fredrick M Pavalko; Angela Bruzzaniti; Melissa A Kacena
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

Review 10.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.